Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 2:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Meloxicam Tablets 15 mg Clear all
Completed Phase 2 Interventional Results available

A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

NCT02078102
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions
Meloxicam, Filgrastim
Drug
Lead sponsor
Sherif S. Farag
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Study of Ovulation in Obese Women

NCT06306131
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5 milligram, Meloxicam 15 milligram, calcium carbonate 750 milligram
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Not applicable Interventional

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

NCT04003350
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Oxycodone, Tramadol, Tylenol, Meloxicam, Gabapentin, Metaxalone, Esomeprazole 20mg
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2019 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

NCT05695352
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery

NCT00945763
View directory record Official record
Conditions
Dental Pain
Interventions
N1539, placebo, Motrin
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

NCT00649675
View directory record Official record
Conditions
Healthy
Interventions
Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

NCT00649077
View directory record Official record
Conditions
Healthy
Interventions
Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 2:08 PM EDT
Recruiting Phase 4 Interventional

Efficacy of Methylprednisolone for Pain Control After ACL Repair

NCT07158476
View directory record Official record
Conditions
ACL Surgery, Pain Management
Interventions
Meloxicam 15 mg, Medrol 4 MG Oral Tablet Includes Medrol Dosepak, Gabapentin 300 mg, Hydrocodone 5Mg/Acetaminophen 325Mg Tab, Ketorolac 10 Mg Oral Tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
13 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

NCT00618163
View directory record Official record
Conditions
Inflammation
Interventions
Meloxicam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 17, 2026, 2:08 PM EDT
Withdrawn Phase 3 Interventional

Multimodal Analgesia in Shoulder Arthroplasty

NCT03586934
View directory record Official record
Conditions
Shoulder Pain, Opioid Use
Interventions
Acetaminophen, Celecoxib 200mg, Celecoxib 400 mg, Ropivacaine, Ketorolac, Acetaminophen Injectable Product, Oxycodone, Tramadol, Morphine Injectable Solution, hydrocodone bitartrate and acetaminophen, Morphine, Oxycodone Hydrochloride, Meloxicam
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 17, 2026, 2:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Meloxicam Tablets Under Fed Conditions

NCT00601887
View directory record Official record
Conditions
Inflammation
Interventions
Meloxicam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 17, 2026, 2:08 PM EDT